Erlotinib Hydrochloride Tablet, Film Coated
Product Images NDC 62332-567

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Erlotinib Hydrochloride (NDC 62332-567). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

30 Tablets (Erlotinib 100mg)

Label for Erlotinib Tablets 100 mg, film-coated oral tablets. The package contains 30 tablets and is labeled for prescription use only. Manufactured by Alembic Pharmaceuticals Limited, India, for Alembic Pharmaceuticals Inc., USA. The label includes storage instructions and a barcode with NDC 62332-566-30.*

FDA Label Image

30 Tablets (Erlotinib 150mg)

Label for Erlotinib Tablets, 150 mg film-coated tablets, oral use. The label specifies a package of 30 tablets. It includes storage instructions, manufacturer details for Alembic Pharmaceuticals Limited and Alembic Pharmaceuticals, Inc., and displays the NDC number 62332-567-30 with barcode. The Alembic logo is shown prominently.*

FDA Label Image

30 Tablets (Erlotinib 25mg)

Label for Erlotinib Tablets 25 mg, film-coated oral tablets. Contains 30 tablets per package. The label shows NDC 62332-565-30, indicates prescription use only, and is labeled by Alembic Pharmaceuticals Inc. Storage instructions and manufacturer information from Alembic Pharmaceuticals Limited, India, are also included along with a barcode and GTIN number.*

FDA Label Image

Figure1 (Erlotinib Figure1)

A Kaplan-Meier curve showing progression-free survival probability over time in months. The graph compares two treatment groups: chemotherapy and erlotinib. Below the x-axis, the number of patients at risk at various time points is displayed for both groups.*

FDA Label Image

Figure 2 (Erlotinib Figure2)

A survival probability chart comparing erlotinib hydrochloride and placebo over time in months. The solid line represents erlotinib, showing higher survival probabilities over 36 months compared to the placebo, indicated by a dashed line. Below the graph is a table showing the number of patients at risk for both groups at various time points.*

FDA Label Image

Figure 3 (Erlotinib Figure3)

A Kaplan-Meier survival curve chart comparing overall survival probability over time in months between patients treated with Erlotinib Hydrochloride and those given a placebo. The chart includes a table indicating the number of patients at risk at various time points for both Erlotinib and placebo groups.*

FDA Label Image

Figure4 (Erlotinib Figure4)

A survival probability curve chart showing overall survival over months for two groups: placebo and Erlotinib. The x-axis represents overall survival in months, ranging from 0 to 36, and the y-axis represents survival probability from 0 to 1. Below the x-axis, a table indicates the number of patients at risk at various time points for each group.*

FDA Label Image

Structure (Erlotinib Str2)

Chemical structure of Erlotinib Hydrochloride, a molecular diagram depicting the arrangement of atoms and bonds that make up the compound.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.